NASDAQ:LUCD 22 January 2026

July 8, 2026, 12:54 PM EDT. AstraZeneca (LSE:AZN) is trading at £143.64, nearly 13% under a fair value estimate of £164.85. The drugmaker's growing push in oncology and siRNA partnerships and a late-stage pipeline in cancer, rare diseases, and heart drugs are seen driving more than $10 billion in potential risk-adjusted peak sales. Shares are up 3.65% over 30 days but down 5.6% over the last 90 days. Total shareholder return for one year is solid at 41.34%. Key risks include pricing pressure and heavy reliance on blockbuster drugs, both of which could weigh on valuation. AstraZeneca trades at 28.7x earnings, well above the sector average of 12.3x, pricing in hopes for further growth.